InvestorsHub Logo
Followers 230
Posts 21490
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Tuesday, 03/08/2022 8:38:38 AM

Tuesday, March 08, 2022 8:38:38 AM

Post# of 404
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
Baudax Bio, Inc.
Tue, March 8, 2022, 5:00 AM·5 min read
In this article:

BXRX
-8.14%

Baudax Bio, Inc.
Baudax Bio, Inc.
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced initiation of a clinical study evaluating the safety and pharmacokinetics (PK) of ANJESO (meloxicam) injection in pediatric patients (ages 2 to <17 years old) following surgery.

https://finance.yahoo.com/news/baudax-bio-initiates-phase-iv-130000680.html


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis